Literature DB >> 2339626

The long-term treatment of steroid osteoporosis with fluoride.

T A Bayley1, C Muller, J Harrison, J Basualdo, W Sturtridge, R Josse, T M Murray, K P Pritzker, R Vieth, S Goodwin.   

Abstract

Twenty-two patients with steroid-induced osteoporosis were studied retrospectively to assess the effects on bone mass of fluoride therapy over 4 years. Thirteen of 19 patients with miscellaneous disorders and 2 with Cushing's syndrome received 1 g calcium/day, 50,000 IU vitamin D (D) weekly, and 40-60 mg/day sodium fluoride (F). Six patients with miscellaneous disorders and one with Cushing's syndrome received only Ca and vitamin D. The mean (+/- SD) cumulative dose of prednisone for fluoride-treated patients at the beginning of the study was 42 +/- 25 g, and for those patients treated with only Ca and vitamin D, 45 +/- 47 g, and during the study the cumulative dose was comparable in both groups. The bone mineral mass of the central skeleton was measured by neutron activation analysis and the results expressed as the calcium bone index (CaBI) which normalizes the results to that of young adults of the same body size (normal range 0.75-1.2). In the 13 patients with miscellaneous disorders treated with fluoride, the mean +/- SD CaBI rose from 0.65 +/- .03 to 0.75 +/- .03 after 3 years p less than 0.001) and to 0.81 +/- .11 at 4 years. Patients without fluoride had an initial mean CaBI of 0.70 +/- .08 and it was not significantly changed over 3 years, 0.68 +/- .09 and 4 years, 0.71 +/- .09. The rise in CaBI in fluoride-treated patients with steroid-induced osteoporosis including Cushing's syndrome was comparable to that of 61 patients with postmenopausal osteoporosis treated with fluoride.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2339626     DOI: 10.1002/jbmr.5650051342

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  11 in total

1.  Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors:  W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

2.  Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride.

Authors:  M Greenwald; D Brandli; S Spector; S Silverman; G Golde
Journal:  Osteoporos Int       Date:  1992-11       Impact factor: 4.507

Review 3.  Management of corticosteroid-induced osteoporosis: a clinician's perspective.

Authors:  S L Silverman
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 4.  Prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  F Eggelmeijer
Journal:  Pharm World Sci       Date:  1998-10

5.  Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.

Authors:  W F Lems; W G Jacobs; J W Bijlsma; A Croone; H C Haanen; H H Houben; M I Gerrits; H J van Rijn
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 6.  Steroid osteoporosis.

Authors:  I R Reid
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  Reversion of the steroid-induced decrease of serum osteocalcin with sodium fluoride.

Authors:  H Rico; J A Cabranes; E R Hernandez; A Barabash; P Romero
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

8.  Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate.

Authors:  E Meys; F Terreaux-Duvert; T Beaume-Six; G Dureau; P J Meunier
Journal:  Osteoporos Int       Date:  1993-12       Impact factor: 4.507

9.  Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis.

Authors:  R Rizzoli; T Chevalley; D O Slosman; J P Bonjour
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 10.  Fluoride therapy of type I osteoporosis.

Authors:  J P Devogelaer; C Nagant de Deuxchaisnes
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.